INT153718

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 10.82
Pain Relevance 2.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (ANGPT1) signal transduction (ANGPT1) extracellular space (ANGPT1)
extracellular region (ANGPT1) plasma membrane (ANGPT1)
Anatomy Link Frequency
plasma 1
PSCs 1
vessels 1
cleavage 1
fibroblast 1
ANGPT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 53 100.00 Very High Very High Very High
rheumatoid arthritis 105 99.84 Very High Very High Very High
Bioavailability 10 99.52 Very High Very High Very High
cytokine 37 99.10 Very High Very High Very High
Inflammation 183 98.64 Very High Very High Very High
cINOD 6 95.04 Very High Very High Very High
COX2 2 83.04 Quite High
fibrosis 9 82.24 Quite High
headache 9 79.68 Quite High
chemokine 89 79.60 Quite High
Disease Link Frequency Relevance Heat
Inflammatory Breast Neoplasms 268 99.84 Very High Very High Very High
Rheumatoid Arthritis 105 99.84 Very High Very High Very High
Synovitis 21 99.72 Very High Very High Very High
Arthritis 45 99.68 Very High Very High Very High
Hypertension 44 98.66 Very High Very High Very High
INFLAMMATION 177 98.64 Very High Very High Very High
Hypoxia 118 98.40 Very High Very High Very High
Cancer 525 98.36 Very High Very High Very High
Apoptosis 58 96.04 Very High Very High Very High
Asthma 58 94.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Among the four epidermal growth factors, 18 angiogenic genes and six cytokines, only seven genes (namely IL-8, VEGF, bFGF, angiopoietin 1, flt-1, Tie-2 and Tie-1) are overexpressed in WIBC-9 when compared with non-inflammatory models [37].
Gene_expression (overexpressed) of angiopoietin 1 associated with inflammation and cytokine
1) Confidence 0.45 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1064141 Disease Relevance 1.27 Pain Relevance 0.20
Angiopoietin-1 (Ang-1) is known to stabilize new vessels, while angiopoietin-2 (Ang-2), in the presence of VEGF, acts as an Ang-1 antagonist, making vessels unstable and promoting vessel sprouting [47].
Gene_expression (antagonist) of Ang-1 in vessels associated with antagonist
2) Confidence 0.43 Published 2010 Journal Respir Res Section Body Doc Link PMC2955663 Disease Relevance 0.54 Pain Relevance 0.13
Among nine angiogenic factors quantified by means of RT-PCR (vascular endothelial growth factor [VEGF], VEGFR1, VEGFR2, Ang-1, Ang-2, TIE-1, TIE-2, COX-2, and basic fibroblast growth factor [bFGF]), the same authors found that Ang-1, TIE-1, TIE-2, and bFGF were strongly expressed in IBC when compared with non-IBC [33].
Gene_expression (expressed) of Ang-1 in fibroblast associated with inflammatory breast neoplasms
3) Confidence 0.35 Published 2005 Journal Breast Cancer Res Section Body Doc Link PMC1064141 Disease Relevance 1.84 Pain Relevance 0.18
VEGF, HIF-1, Ang1, Tie2, and survivin are all expressed in the arthritic synovium [16,25].
Gene_expression (expressed) of Ang1 in synovium associated with arthritis
4) Confidence 0.28 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592799 Disease Relevance 0.79 Pain Relevance 0.33
PSCs expressed several angiogenesis-regulating molecules including VEGF receptors, angiopoietin-1, and Tie-2.
Gene_expression (expressed) of angiopoietin-1 in PSCs
5) Confidence 0.25 Published 2008 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 18669622 Disease Relevance 1.43 Pain Relevance 0.20
the expression of Ang-1 and hence the angiogenic process through the
Gene_expression (expression) of Ang-1
6) Confidence 0.19 Published 2008 Journal PPAR Research Section Body Doc Link PMC2366048 Disease Relevance 0.48 Pain Relevance 0.07
Similarly, the angiopoietins Ang1 and Ang2, and their cellular receptor Tie2, which are all widely expressed in RA synovitis, are regulated by both hypoxia and TNF-?
Gene_expression (expressed) of Ang1 associated with hypoxia, synovitis and rheumatoid arthritis
7) Confidence 0.13 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC1064874 Disease Relevance 1.19 Pain Relevance 0.32
In healthy human subjects, doses of between 40 and 640 mg of aliskiren exert a dose-dependent reduction in PRA and Ang I and Ang II levels.
Gene_expression (levels) of Ang I
8) Confidence 0.07 Published 2008 Journal Pharmacol Rep Section Abstract Doc Link 19066408 Disease Relevance 0.39 Pain Relevance 0.20
In healthy humans, aliskiren of doses between 40 and 640 mg exerts a dose-dependent reduction in PRA, Ang I, and Ang II levels.
Gene_expression (levels) of Ang I
9) Confidence 0.06 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.09 Pain Relevance 0
When this increase occurs during treatment with ACEIs and ARBs, the result is increased levels of PRA but during treatment with aliskiren, the effect of increased renin levels is blocked, so the levels of Ang I and Ang II, as well as PRA, are all reduced.52 The clinical trials do not report any major adverse effects of aliskiren compared with ARBs or ACEs being generally well tolerated by all patients.
Gene_expression (levels) of Ang I
10) Confidence 0.06 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 1.10 Pain Relevance 0.16
As DRI reduces PRA, the production of Ang I decreases, resulting in less substrate availability for conversion to Ang II by ACE or other enzymes.
Gene_expression (production) of Ang I
11) Confidence 0.06 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0 Pain Relevance 0
Again, aliskiren at a dose of 300 mg decreases PRA in hypertensive patients by approximately 50%–80%51,52 and reduces PRA and plasma levels of Ang I and Ang II for 48 hours.53 Furthermore, urinary aldosterone was reduced at a dose of 80 mg or more, and sodium extraction was increased to 91% at a dose of 640 mg.54 Compared with valsartan, aliskiren more strongly decreases the activity of renin in the circulation and reduces the excretion of urinary aldosterone for a longer period.53,55 Following oral administration, peak plasma concentrations of aliskiren are reached within 1–3 hours.52,53,56–58 The plasma half-life of aliskiren in humans shows a slow terminal elimination at 23–70 hours59–61 and approximately 47%–51% of aliskiren is bound by plasma proteins in humans, independent of the concentration.59,62,63 Based on in vitro studies, the major enzyme responsible for its metabolism appears to be Cytochrome P450 (CYP3A4).
Gene_expression (levels) of Ang I in plasma associated with hypertension
12) Confidence 0.06 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2922316 Disease Relevance 0.10 Pain Relevance 0
A recently completed study of more than 100 colorectal resection patients demonstrated that after either open or minimally invasive resection (on both PODs 1 and 3), Ang 1 levels were significantly lower and Ang 2 levels significantly higher compared with the preoperative results for both benign and cancer indications.
Gene_expression (levels) of Ang 1 associated with cancer
13) Confidence 0.05 Published 2009 Journal Surg Endosc Section Body Doc Link PMC2814196 Disease Relevance 0.10 Pain Relevance 0
expression of angiogenic regulatory genes, including VEGF, ang-1, and ang-2 are
Gene_expression (expression) of ang-1
14) Confidence 0.04 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.12 Pain Relevance 0.30
AngI itself is produced by enzymatic cleavage of the angiotensinogen precursor by renin.
Gene_expression (produced) of AngI in cleavage
15) Confidence 0.01 Published 2008 Journal Mol Cancer Section Body Doc Link PMC2615789 Disease Relevance 0.37 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox